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Abstract
Background: We aim to provide a systematic study of the impact of white matter
(WM) spill-in on the calculation of standardized uptake value ratios (SUVRs) on Aβ-
negative subjects, and we study the effect of including WM in the reference region
as a compensation. In addition, different partial volume correction (PVC) methods are
applied and evaluated.
Methods: We evaluated magnetic resonance imaging and 18F-AV-45 positron
emission tomography data from 122 cognitively normal (CN) patients recruited at
the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Cortex SUVRs were obtained
by using the cerebellar grey matter (CGM) (SUVRCGM) and the whole cerebellum
(SUVRWC) as reference regions. The correlations between the different SUVRs and the
WM uptake (WM-SUVRCGM) were studied in patients, and in a well-controlled
framework based on Monte Carlo (MC) simulation. Activity maps for the MC
simulation were derived from ADNI patients by using a voxel-wise iterative process
(BrainViset). Ten WM uptakes covering the spectrum of WM values obtained from
patient data were simulated for different patients. Three different PVC methods were
tested (a) the regional voxel-based (RBV), (b) the iterative Yang (iY), and (c) a
simplified analytical correction derived from our MC simulation.
Results: WM-SUVRCGM followed a normal distribution with an average of 1.79 and a
standard deviation of 0.243 (13.6%). SUVRCGM was linearly correlated to WM-SUVRCGM
(r = 0.82, linear fit slope = 0.28). SUVRWC was linearly correlated to WM-SUVRCGM (r =
0.64, linear fit slope = 0.13). Our MC results showed that these correlations are
compatible with those produced by isolated spill-in effect (slopes of 0.23 and 0.11).
The impact of the spill-in was mitigated by using PVC for SUVRCGM (slopes of 0.06
and 0.07 for iY and RBV), while SUVRWC showed a negative correlation with SUVRCGM
after PVC. The proposed analytical correction also reduced the observed correlations
when applied to patient data (r = 0.27 for SUVRCGM, r = 0.18 for SUVRWC).
(Continued on next page)
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Conclusions: There is a high correlation between WM uptake and the measured
SUVR due to spill-in effect, and that this effect is reduced when including WM in the
reference region. We also evaluated the performance of PVC, and we proposed an
analytical correction that can be applied to preprocessed data.
Keywords: Amyloid, PET, Quantification, SUV, PVE
Background
Brain amyloidosis is one of the best-defined biomarkers for Alzheimer’s disease (AD),
playing a central role in the novel National Institute on Aging and Alzheimer’s Associ-
ation (NIA-AA) AT(N) framework [1]. Positron emission tomography (PET) using
fibrillary amyloid-β (Aβ PET) tracers is one of the main methodologies to assess this
biomarker, together with cerebrospinal fluid (CSF) Aβ42 and Aβ42/Aβ40 measure-
ments. In its simplest form, Aβ PET can be classified as positive/negative through
visual inspection [2] or by applying a threshold to an image-derived parameter [3]. Des-
pite Aβ deposition in the grey matter (GM) occurs on a continuum, categorical classifi-
cation of individual subjects is relevant for clinical diagnosis [4], for the inclusion of
subjects in therapeutic trials [5], and for distinguishing Aβ-dependent and independent
changes in brain cognition, structure, and function [6].
The most used image-derived parameter in Aβ PET is the SUVR (standardized up-
take value ratio) between a target region, a compound of cortex regions known to be
involved in AD, and a reference region. The choice of an optimal reference region
implies taking into account some theoretical requirements, such as to have similar per-
fusion characteristics to the target region, to be free of specific binding sites (for the
particular case, free of Aβ plaques) and to have a non-specific binding similar to the
target region [7], among others. The cerebellar GM (CGM) has been traditionally used
as a reference region for the quantification of Aβ PET, since it fulfills most of these
criteria, with the exception of Aβ plaques appearing in the CGM at advanced stages of
the disease [8] and in some genetic variants of AD [9]. Regarding this, recent studies
highlighted that the effect of cerebellar Aβ pathology on SUVR quantification would be
negligible, even in subjects with high cortex Aβ burdens [10]. Nevertheless, recent pub-
lications have pointed that alternative regions such as the whole cerebellum (WC), in-
cluding both GM and white matter (WM) [11, 12], or the whole brain WM alone as a
reference region [13–15], could provide improved results when compared with CGM.
Including WM into the reference region could have some potential advantages, such as
(a) the WM is a high-uptake region, which will lead to higher voxel count-rates and
thus, less variability in the measurement of the reference region mean values used to
calculate SUVR [16]; (b) WM is a large region, providing a better resistance to small
registration errors [17]; and (c) WM is usually centered on the field-of-view, being less
affected by scatter correction errors that usually occur near the edge of the scanner
[14]. On the other hand, WM does not fulfill the aforementioned criteria for a suitable
reference region. In particular, WM has significant non-specific binding compared to
the cortex GM [18], and the underlying mechanism of Aβ uptake in the WM for the
different radiotracers is poorly understood [19]. Some authors have suggested that it
could to be related to increased tracer lipophilicity or to specific binding to β-sheet
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structured myelin basic proteins [20] and as such, related to age-associated demyelin-
ation. Furthermore, recent studies have suggested that WM uptake might be more rele-
vant to the evolution of the disease than previously expected [19], with WM uptake
increasing with age and with disease progression.
Thus, the good performance of these alternative reference regions including WM re-
mains an interesting field of exploration. An important fact to take into account when
discussing Aβ PET quantification is that it can be further hardened by the limitations
of PET imaging [7]. One of the most relevant problems regarding Aβ PET images is
the partial volume effect (PVE), defined as the spill-over of counts between different
image regions due to the limited spatial resolution of the PET images [21]. The PVE is
often regarded as two separate effects: the counts that go from the target region to
adjacent regions (spill-out) and the counts that go from these adjacent regions into the
target region (spill-in). These PVEs are proportional to the differences in uptake
between the target and the adjacent region (contrast), being more prominent from hot
to cold regions [22], and to the size of the regions, as, in relative terms, small regions
are more sensitive to PVE than larger regions [23]. Thus, two different effects must be
considered in the estimation of SUVR from Aβ PET images. First, the spill-out activity
from the GM to the WM and CSF due to cortical thickness and its variations due to
atrophy in longitudinal studies. This effect has been broadly studied, concluding that
different PVE corrections (PVC) provide more consistent longitudinal results [24, 25].
Second, the spill-in activity from the WM into the GM, which might be especially
relevant for studies where primarily amyloid-negative patients are used, such as in the
calculation of SUVR thresholds. In a recent study [26], a visual inspection of SUVR
borderline false-positive cases was related to high radiotracer retention in WM. In
addition, other publications [27] reported a correlation between white and gray matter
uptake in 11C-Pittsburgh compound B (11C-PIB) in cognitively normal (CN) patients,
and how this correlation disappeared after applying PVC. Spill-in in Aβ-negative
patients have also been evaluated focusing on its effect on kinetic parameters, demon-
strating a significant bias of the non-specific binding components in GM due to WM
spill-in both in 18F-based and 11C-based tracers [28, 29]. These latter findings could ex-
plain why reference regions containing WM seem to be more robust, as the inclusion
of WM counts into the reference region could partially compensate for this effect.
In this work, we aim to provide a systematic study of the impact of WM spill-in ac-
tivity on the calculation of SUVR values when using different reference regions with
and without WM. For this, we present a MC methodology for simulating realistic amyl-
oid PET studies. We also propose a simple analytical correction.
Methods
Patient cohort
Patient data used in the preparation of this article were obtained from the Alzheimer’s
disease Neuroimaging Initiative (ADNI) database [30]. ADNI was launched in 2003 as a
public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The
primary goal of ADNI has been to test whether serial magnetic resonance imaging
(MRI), PET, other biological markers, and clinical and neuropsychological assessment
can be combined to measure the progression of mild cognitive impairment (MCI) and
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early AD. In this work, we included 122 CN patients recruited at the start of ADNI2
who underwent a baseline structural MRI and 18F-AV-45 PET scan.
Image acquisition and preprocessing
PET images were acquired by using dynamic 3D acquisitions of 5-min frames from 30
to 60 min after the injection of 370 MBq of 18F-AV-45. Every image was reviewed for
protocol compliance by the ADNI PET Quality Control team. Currently, there are four
types of processed PET image data available for download the ADNI database [31]:
a) Co-registered dynamic: the acquired dynamic frames are recombined into a co-
registered dynamic image set co-registering frames two to four to the first frame to
avoid movement artifacts.
b) Co-registered averaged: 30 min static image obtained averaging the frames on the
previously described dynamic image.
c) Co-registered averaged images standardized: each subject’s co-registered averaged
image is reoriented into a standard template
d) Co-registered averaged images standardized and smoothed: the above-mentioned
images are filtered with a scanner-specific filter function (can be a non-isotropic
filter) to produce images of a uniform isotropic resolution of 8 mm FWHM.
For carrying out this work, images in preprocessing level (b) were downloaded. Any
extra processing was performed in-house as detailed in the following sections.
18F-AV-45 PET quantification
Image processing was performed using the Statistical Parametric Mapping (SPM) soft-
ware package version 12 [32]. PET and MRI images were co-registered using the MRI
image as the reference space. MRI images were segmented into GM, WM, CSF, bone
and soft tissue, and normalized to the Montreal Neuroimaging Space (MNI), by using
the Local Adaptative Segmentation (LAS) and the Diffeomorphic Anatomical Registra-
tion Through Exponentiated Lie Algebra (DARTEL) normalization [33] tools provided
by the Computational Anatomy Toolbox [34, 35]. The inverse of the normalization
transformation matrix was used to take the Hammersmith atlas [36] back into the
native MRI space. Voxel tissue probability maps generated by the segmentation were
binarized to generate GM, WM, and CSF masks by using a GM favoring approach.
Voxels in the GM-WM and GM-CSF interfaces were considered GM when GM prob-
ability was > 0.1 unless WM (or CSF) probability was bigger than 0.5 [37]. The same
approach was applied in the CSF-WM interface, favoring CSF over WM. The inverted
Hammersmith atlas was multiplied by the GM mask to generate a GM patient-specific
atlas. WM and CSF were added to the patient-specific atlas as uniform tissues (results
of the different steps of the image processing are shown in Additional file 1:
Supplementary Figure S1). PET images were smoothed to achieve a uniform isotropic
resolution of 8 mm FWHM with the scanner-dependent smoothing values provided by
ADNI (see Additional file 1: Supplementary Table S1) when required. The average
cortex uptake was measured by using a composite region of interest (ROI) integrating
the GM from the anterior and posterior cingulate, the precuneus, and the frontal,
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lateral temporal, and lateral parietal cortex. The WM mask was used as a ROI to
calculate the average WM uptake. We also used an eroded WM ROI, generated as
described in previous works [16]. Cortex SUVR values were obtained by using both
the CGM (SUVRCGM) and the WC (GM + WM) (SUVRWC) as reference regions.
An example of the different ROIs used in the quantification process is shown in
Fig. 1. WM and eroded WM uptakes were normalized by the CGM value (WM-
SUVRCGM). The measured SUVR values were compared, when possible, with those
provided by the ADNI PET Core at Berkeley [38], for validation purposes (see
Additional file 1: Supplementary Figure S2).
Relation between WM-SUVR and cortex SUVR
Firstly, the variability of WM-SUVRCGM across CN amyloid-negative subjects was stud-
ied after removing those CN patients categorized as amyloid-positive by the 1.11
SUVRWC ADNI threshold. The histogram of WM-SUVRCGM values was then fitted to
a normal distribution. The correlation between cerebellum WM (inside the reference
region) and the rest of the WM were evaluated to ensure that the inclusion of cerebel-
lar WM into the reference region could positively compensate for WM spill-in, as
suggested by our hypothesis. Then, the relation between cortex SUVR (SUVRCGM and
SUVRWC) and WM-SUVRCGM measurements was assessed. This analysis was
performed by using both the whole WM and the eroded WM as defined by ADNI.
Monte Carlo simulation
The impact of the changes in WM uptake on the quantification of cortex SUVR was
evaluated in a well-controlled framework using Monte Carlo (MC) simulations. To this
end, simulated 18F-AV-45 PET images were generated using realistic activity maps and
widely validated MC simulation techniques:
Generation of realistic activity maps
Patient-specific activity maps were generated by using the BrainViset (voxel-based
iterative simulation for emission tomography) iterative procedure, which is ex-
plained in detail elsewhere [39]. In brief, initial activity and attenuation maps were
generated by filling the patient-specific atlas with activity values from the original
PET image and with the corresponding attenuation values for each of the seg-
mented tissues (see Additional file 1: Supplementary Figure S1). After MC simula-
tion, the reconstructed images were compared voxel-wise with the corresponding
ADNI PET studies in an iterative process where the activity inputs maps were
Fig. 1 Different ROIs used for the quantification of 18F-AV-45 PET. From left to right: cortex composite
region, CGM, WC, WM, and eroded WM ROIs
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being modified at each iteration until the correlation coefficients between the ori-
ginal ADNI images and the simulated images were ≥ 0.99. This procedure was per-
formed for five amyloid-negative patients acquired using a GE Discovery STE
scanner (ADNI IDs 4579, 4580, 4254, 4276, 4421). After obtaining the activity
maps for each patient, 10 different ground truth WM-SUVRCGM values were intro-
duced into the obtained activity maps in order to cover all the spectrum of WM-
SUVRCGM derived from the patient data. The theoretical SUVRCGM was maintained
(SUVRWC values were not constant as our WM variability included WM on the
cerebellum). This resulted in 50 activity maps (10 per patient) and 5 attenuation
maps (1 per patient) as inputs for our MC simulation. A schematic view of the
activity map generation process is shown in Fig. 2.
Simulated data
MC simulations were performed using the open-access package SimSET (v.2.9.2)
(simulation system for emission tomography) [40–42]. SimSET includes detailed phys-
ics simulation (positron range and non-colinearity, photoelectric effect, coherent scat-
tering, and incoherent scattering) for energies of interest in nuclear medicine (below 1
MeV). The scanner MC model for the GE Discovery STE scanner was implemented as
presented by previous works [43]. The model was tested using the NEMA NU-2007
protocol. Simulated NEMA results were validated over the clinical scanner present at
CIMES (Centro de Investigaciones Medico Sanitarias, Fundación Universidad de
Málaga). In all the NEMA sections, the percentage error was found below 10%.
The simulation times were adjusted to replicate the 20-min total acquisition times in
the ADNI protocols. Since the PET scanner was modeled as a solid cylinder of BGO,
the simulation times were adjusted in order to match the sensitivities by using the
Fig. 2 Layout of the BrainViset procedure used for the generation of realistic activity maps for our
MC simulation
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NEMA sensitivity test results. The simulations were performed on a desktop computer
including an Intel® Core™ i7-4790K CPU providing 8 cores at 4.00 GHz each (Intel
Corporation, Santa Clara, CA, USA) and 32 GB of DDR4 RAM. Each simulation was
divided into eight sub-processes in order to use the eight threads of the processor. Each
simulation consumed around 8 h of CPU time.
Image reconstruction
The image reconstruction of the simulated data was performed with the ordered subset
expectation maximization (OS-EM) [44] as implemented in STIR (Software for Tomo-
graphic Image Reconstruction) [45, 46]. STIR is an Open Source PET reconstruction
toolkit maintained by the University College London (UCL). For more information,
head to the STIR wiki [47]. Reconstruction parameters were set to fit those of the scan-
ner. Five full iterations were performed (35 sub-iterations, 7 subsets). Neither post-
filtering nor inter-iteration filtering was applied. The matrix and voxel size of the
reconstructed images were 128 × 128 × 47 and 1.95 mm × 1.95 mm × 3.27 mm.
Simulated data analysis
SUVRCGM, SUVRWC, and WM-SUVRCGM for the simulated data were calculated as
described below for the patient data. Data was analyzed for PVC and non-PVC data.
For each case, a single fit with a unified slope and variable intercept for each of the
simulated SUVRs was obtained by using a general linear model. The independence of
the slope for each individual subject with the simulated SUVR was tested by using a
linear mixed model and introducing a random term to assess this dependency.
Partial volume correction
Two PVC methods were tested on the simulated data: (a) the region-based voxel-wise
(RBV) and (b) the iterative Yang (iY) methods. The corrections were applied without
applying the smoothing to 8-mm included in the ADNI processing, directly convolving
by the point-spread function (PSF) calculated for our MC simulation model. The cor-
rections were performed by using the PETPVC toolbox [48]. This open-source package
provides the necessary tools for applying a wide range of PVC methods. The toolbox is
developed using C++ and optimized for fast execution times.
For the applied corrections, a segmented PET image is used as an input for the PSF
deconvolution (see Additional file 1: Supplementary Figure S1). The segmented PET
consists of an MRI-derived personalized atlas (generated as defined in the SUVR quan-
tification section) filled with ROI values based on the PET image.
The RBV PVC [25] is an extension of the popular geometrical transfer matrix (GTM)
method and the voxel-wise correction of Yang et al. [49]. The mean ROI activity values
are calculated using the GTM, and then a voxel-by-voxel correction is performed in
order to produce a corrected image by performing a voxel-wise multiplication of the
uncorrected PET image with a PVE correction factor. This factor relates PVE corrected
ROI values obtained by GTM with smoothed segmented PET voxel values. RBV was
chosen for this work before the original GTM since it provides a corrected image,
which facilitates the calculation of corrected SUVR values using the same methodology
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used for uncorrected images. In addition, RBV accounts for within-compartment
variability, preventing biases in GM PVC corrected values due to WM variability.
The iY method [50] extends the aforementioned voxel-wise Yang method [49]
process. In contrast with RBV, instead of calculating the regional mean values via the
GTM, the values are estimated from the PET data itself. The Yang correction is applied
and the mean value estimates are recalculated. This process is iterated several times
(for this work, we used 10 iterations), updating the PET image at each iteration with
the input of the previous iteration, providing more accurate correction factors.
Linear correction of WM spill-in
In addition, a simple analytical correction was tested. The analysis of the simulated data
was used to extract slope the theoretical correlating WM uptake and SUVRs values.
The slopes were obtained for the different reference regions and then used to correct
the dependency of SUVR with WM-SUVRCGM over the patient data. Corrected SUVR
values were obtained by applying a linear function that estimates the SUVR for the cen-
ter of the previously estimated Gaussian (WM-SUVRCGM = 1.79) using the measured
SUVRCGM and SUVR. The correlation between corrected SUVRs and WM-SUVRCGM
was assessed using Pearson’s correlation coefficients after the correction and compared
with the original results.
Results
Patient data analysis
Of the 122 analyzed CN patients, 13 were discarded because of problems with PET/MR
co-registering or MRI normalization or segmentation during the image analysis. Of the
remaining, 27 (22%) were found amyloid-positive according to ADNI SUVRWC thresh-
old, and were also excluded from the subsequent analysis. On amyloid-negative
patients, WM-SUVRCGM ranged from 1.32 to 2.44, following a normal distribution with
an average of 1.79 and a standard deviation of 0.24 (13.6%) (see Additional file 1:
Supplementary Figure S3). Cerebellum WM, which is included inside the reference re-
gion for the calculation of SUVRWC, increased at a lower ratio (slope = 0.76, R
2= 0.71)
than the rest of the WM.
Figure 3 shows the relation of the measured SUVRCGM (orange) and SUVRWC (blue)
with WM-SUVRCGM on amyloid-negative patients. Both provided positive linear rela-
tions with Pearson’s coefficients of 0.82 (SUVRCGM and WM-SUVRCGM) and 0.64
(SUVRWC and WM-SUVRCGM). The increase of SUVRCGM with WM-SUVRCGM was
more pronounced than that of SUVRWC (slopes of 0.28 and 0.13, respectively). It is
valuable to mention that no significant differences were found when using eroded WM,
showing similar Pearson’s coefficients (0.80 and 0.61, respectively) and slopes (see
Additional file 1: Supplementary Figure S4). Quantified values for each individual pa-
tient can be found at Additional file 1: Supplementary Table S2.
Monte Carlo simulation
Realistic activity and attenuation maps were extracted for five ADNI patients from the
previous cohort, with measured WM-SUVRCGM of 1.56, 2.00, 2.12, 2.13, and 2.33. The
resulting activity maps had theoretical SUVRCGM of 0.96, 1.01, 1.11, 1.21, and 1.21. For
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each of the patients, WM was modified by multiplying the WM by a constant to pro-
duce maps with theoretical WM-SUVRCGM values of 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8,
3.0, and 3.2, for each constant SUVRCGM value. Simulated SUVRWC were variable since
the variation of WM-SUVRCGM also affected the WM in the cerebellum. An example
of the different simulations for one of the patients (ADNI RID 4579) can be observed
in Fig. 4.
The simulated images were processed using the same steps detailed for patients. The
measured relation between measured SUVRCGM, SUVRWC, and WM-SUVRCGM on the
simulations showed a slope of 0.226 ± 0.002 for the relation between SUVRCGM and
WM-SUVRCGM and a slope of 0.108 ± 0.002 for the relation between SUVRWC and
WM-SUVRCGM. The results show that for the simulated SUVR ranges, there is not a
dependency between the slope and the SUVR value, with estimates confidence levels
compatible with zero. The results for the smoothed images can be observed in Fig. 5.
Fig. 3 Relation between WM-SUVRCGM and GM SUVRs. Orange dots (and orange line) are for the CGM as a
reference region (SUVRCGM), while the blue dots (and blue line) are for the WC as a reference region (SUVRWC)
Fig. 4 Simulations of the 10 activity maps with different WM uptakes and a fixed cortex uptake for one of
the simulated patients
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Partial volume correction
The ability of PVC to reduce the measured effect was evaluated by applying different
PVC methods to the simulated data (examples of images processed by the different
PVCs are provided in Additional file 1: Supplementary Figure S6). The results of the
quantification for the PVC data are shown in Fig. 6. For the iY correction, the general
linear model fitted to an average slope of 0.059 ± 0.002, while for the RBV the average
slope was 0.070 ± 0.002, for SUVRCGM.
From the results, it is clear that applying PVC can reduce the spill-in, but it should
be noted that for the two used methods, the intercept values for the different patient
fits vary significantly. These variations between the different PVCs were patient-
dependent, with iY providing a more accurate representation of the ground truth
SUVRCGM for low WM-SUVRCGM (Additional file 1: Supplementary Figure S7 shows a
comparison between the different measured values for RBV and iY and the ground
truth simulated SUVRCGM). It is also important to point that we observed a reduction
of SUVRWC when increasing WM-SUVRCGM when PVC is applied.
Linear correction
Patient data was corrected by applying the linear slope extracted from the MC simula-
tion. Corrected SUVR values were obtained by taking them to the average WM uptake,
Fig. 5 Relation between the measured SUVRs and WM-SUVRCGM. Each color represents one of the simulated
patients. Values were measured for SUVRCGM (left) and SUVRWC (right). Threshold values of SUVRCGM = 1.30 and
SUVRWC = 1.11 are plotted for representation purposes only
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the center of the previously estimated Gaussian (WM-SUVRCGM = 1.79). The same
correction was applied to SUVRWC by replacing with the corresponding slope:
SUVRCGM−correc¼0:226 1:79−WMSUVRCGMð ÞþSUVRCGM
SUVRWC−correc¼0:108 1:79−WMSUVRCGMð ÞþSUVRWC
Pearson’s correlation coefficient between SUVRCGM and WM-SUVRCGM after the
correction was r = 0.27. Pearson’s correlation coefficient between SUVRWC and WM-
SUVRCGM after the correction was r = 0.18. The effect of this correction over our pa-
tient cohort is shown in Fig. 7.
Discussion
Several publications have recently pointed to the fact that reference regions including
WM provide better correlations with CSF levels and less longitudinal variability than
the cerebellum cortex [11–14]. Some points in favor of WM reference regions could be
that WM is a larger region potentially leading to less noise, more resistant to small de-
grees of misregistration and in the center of the scanner field-of-view. Nevertheless,
WM uptake is known to be non-specific, and its mechanisms are largely unknown, so
it is not an ideal candidate for a reference region. In this work, our main hypotheses
was that an additional point to take into account is that including WM into the refer-
ence region will also compensate (at least partially), the spill-in of WM counts into the
cortex, which would lead otherwise to artificially increased SUVR values, especially for
healthy controls with low cortex uptake [26]. In order to assess this, we have investi-
gated the variability of the WM uptake across a population of healthy patients, and
Fig. 6 Relation between the measured SUVRs and WM-SUVRCGM for PVC corrected images. Each color
represents one of the simulated patients. Values are represented for SUVRCGM (left) and SUVRWC (right) and
for iY (top) and RBV (bottom) PVCs
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then we used MC simulation to evaluate, first, if these changes are enough to produce
significant variations in cortex SUVR values, and second, if a reference region including
WM (in our case the WC (GM+WM) effectively minimizes these variations.
WM values on the evaluated patient cohort were in the range of 1.32–2.44, following
a normal distribution centered in 1.79 with a percentage standard deviation of 13.6%.
These values are in good agreement with previously published results [51] that reported
WM averages of 1.92 ± 0.23 for healthy patients. We also observed that the increase of
uptake in the cerebellum WM was slower than in the rest of the WM (ratio approxi-
mately of ≈ 0.8). This difference could be attributed to PVE itself, as the size of the
cerebellum WM is relatively small when compared to the rest of the WM. We observed
a positive correlation between measured SUVR values and WM uptake, which was
more prominent when using the CGM (r = 0.82) as a reference region, than when using
a reference region containing WM, as the WC (r = 0.64). We observed that SUVRCGM
increased by 0.28 units when WM-SUVRCGM increases one unit, while SUVRWC
increased 0.13 units when WM-SUVRCGM increased one unit. This correlation is
significantly higher than previously reported in 11C-PIB [27]. This can be related to
the fact that WM retention in 18F-based tracers is significantly higher than in 11C-
PIB [52]. In addition, in the cited publication, authors use both amyloid-positive
and amyloid-negative CN patients, which would also reduce the observed correl-
ation (see Additional file 1: Supplementary Figure S5). We also showed that the
correlation is present independently of using all the WM or only the eroded WM
as defined by ADNI [16], pointing that the spill-out of cortex counts into the WM
is irrelevant in comparison with the WM spill-in. This is explained, again, by the
Fig. 7 ADNI data corrected applying the linear relation obtained from Monte Carlo simulation. Blue points
represent uncorrected data, while orange points represent corrected data. Values are represented for
SUVRCGM (left) and SUVRWC (right). Threshold values of SUVRCGM = 1.30 and SUVRWC = 1.11 are plotted for
representation purposes only
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fact that we are evaluating only amyloid-negative patients, where WM uptake is
significantly higher than cortex uptake.
Regarding our MC experiments, we simulated realistic maps with fixed cortex uptake,
and variable WM uptake, and evaluated the variations of measured SUVRs following
the same methodology used in patients. This way we isolate WM spill-in from any
other physical or physiological effects, allowing a precise investigation of this particular
effect. These experiments showed that the introduced WM variability produced corre-
lations similar to those observed in patients. SUVRCGM increased by 0.23 units when
WM-SUVRCGM increases one unit, while SUVRWC increased 0.11 units when WM-
SUVRCGM increased one unit.
To evaluate the ability of PVC methods to remove this effect, we tested two differ-
ent methods, iY and RBV, over the simulated data. These methods were used instead
of more widespread alternatives such as Müller-Gärtner (MG) and GTM, since they
have the ability to produce a corrected image, enabling to reproduce the exact same
processing pipeline (with the removal of the smoothing to 8 mm) used in patient data.
Both methods were able to reduce the observed dependency, reducing the aforemen-
tioned 0.23 slope for SUVRCGM to 0.06 and 0.07, respectively. It is important to re-
mark that corrected SUVR for the different PVC methods were qualitatively different,
something that has been previously highlighted in other publications [53, 54]. Once
PVE was corrected, using the WC as the reference region produced a reduction of the
SUVRs as WM increased. On the one hand, this finding reinforces our hypothesis of
the compensation of spill-in counts by including WM counts as a key to the good
performance of these reference regions. On the other hand, it seems to contradict
previous findings pointing to the combination of WM reference regions and PVC as
optimal for longitudinal reliability of the measurements and threshold-based separation
[15, 55], but this is not necessarily the case. In both cases, both amyloid-negative and
positive subjects compose the patient cohort, and WM emerges as the best-suited
reference region based on longitudinal performance. In such a case of study, spill-out due
to atrophy and cortical thickness variations might play a more prominent role than spill-
in, since reduced WM-GM contrast is expected. Furthermore, WM variability has been
shown to influence the accuracy of MG-based PVCs in cortical GM and also CGM, while
RBV and iY account for within-compartment variability [25], so our findings might still
be compatible with those in these publications.
In brief, our results suggest that the correlation observed in patient data is largely
produced by WM spill-in, and that it is reduced when introducing WM into the refer-
ence region. This could be an explanation as to why reference regions including WM
perform better than CGM in longitudinal studies [13–15]. In addition, we observed
that a very similar reduction of the effect of the PVE could be obtained by applying
PVC and using CGM as a reference region, as it can be observed in Fig. 6. This later
implementation will be more convenient, as CGM is, theoretically, a better reference
region. Nevertheless, further work would be required to investigate the effect of iY,
RBV and other PVC methodologies on the analysis of longitudinal data.
Finally, we evaluated the performance of a simple analytical correction, by applying
the observed slope obtained in our MC simulation (that is strictly derived from PVE) to
the patient data, in order to remove the previously described dependency. The results
are presented in Fig. 7. This simple correction was effective in reducing the previously
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observed correlation coefficients between SUVRCGM and WM-SUVRCGM (from 0.82 to
0.27) and between SUVRWC and WM-SUVRCGM (from 0.64 to 0.18). It is important to
remark that, as it can be observed on Fig. 7 (bottom), applying our linear correction
does not remove all the correlation. This could be explained by the differences in
resolution between our MC model and the real PET scanner (5–10%), or by other factors
correlating SUVRCGM and WM-SUVRCGM that were not taken into account on our MC
simulation. The main limitation of the presented correction is that the presented formulas
will be applicable only for the ADNI cohort, or for other studies that have adopted the
ADNI processing methodology, and only for amyloid-negative patients. Nevertheless, this
type of correction might be of interest since it does not require additional processing of
the image and it can be applied directly to previously calculated data tables and SUVR
values, such as those provided by ADNI PET processing core at Berkeley. For applying
this correction to cohorts with different image processing pipelines, the simulation needs
to be repeated in order to recalculate the slopes and average WM-SUVRCGM for the pro-
posed formulas. About the application on amyloid-positive patients, a clear limitation of
the proposed methodology is that high cortex uptake will change the contrast relations
between GM and WM, and thus, the amount of PVE and the calculated slope might also
change [23]. A much more complex analysis including simulations for amyloid-positive
patients in the whole range of SUVRs would be needed to generalize the proposed correc-
tion to the entire cohort. Nevertheless, the correlation observed in Fig. 3 is expected to
decrease when the cortical amyloid load is high.
About some additional limitations of the present work, our activity maps were ex-
tracted only for 5 of the initial cohort of 82 patients, all of them were scanned with the
GE Discovery STE scanner. Applying the derived formulas to the entire cohort, we are
assuming, first, that the smoothing values proposed by ADNI (see Additional file 1:
Supplementary Table S1) correctly harmonize the resolution of the scanners in the co-
hort, and second, that the range of simulated ground truth SUVR values (0.9–1.21) is
representative of the values on the cohort. Future work could expand the presented
simulations by including different scanners and more ground truth SUVRs.
Conclusions
We have observed that there is a significant positive correlation between measured
SUVRs and WM uptake in amyloid-negative patients, and that this correlation is re-
duced by using reference regions including WM. This could be an explanation for the
good performance of reference regions including WM. By using MC simulation, we
demonstrated that this correlation is largely produced by PVE, and that it can be re-
moved by using PVC. These results shall be of special interest for situations where
primarily healthy populations are used, such as the calculation of SUVR positivity
thresholds. We have proposed a correction that can be applied directly to previously
calculated SUVR values in such cases.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s40658-019-0258-7.
Additional file 1: Figure S1. Detailed view of some of the results of the image processing and their relationships.
On the top: Original MRI and PET images and results of the MRI normalization (warped atlas) and segmentation.
On the bottom: GM patient-specific atlas generated from the warped atlas and the GM. PVC labels including WM and
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CSF together with the GM specific atlas and BrainVIset input (iteration 0) activity and attenuation maps. Figure S2.
Comparison of SUVR values measured on our lab (x-axis) and data calculated by the ADNI PET Core at Berkeley (y-axis)
for our final subject sample. Average differences between Berkeley calculations and ours were found to be ± 4.6%.
These small differences are mainly due to different processing pipelines, such as different segmentation methods (CAT
vs. Freesurfer), atlas (Hammersmith vs Desikan) or quantification space (patient vs. MNI). Figure S3. Distribution of WM
values across the studied ADNI2 sub-sample. Only amyloid-negative patients are presented. The bars represent the
number of patients on each bin of the histogram, while the black solid line represent the Gaussian distribution of the
histogram. Figure S4. Visual comparison of the correlations of cortex SUVR (x-axis) with WM-SUVRCGM, using both the
whole WM (green) and the Eroded WM (purple) as WM regions. Figure S5. Relation between WM-SUVRCGM (x-axis)
and GM SUVR using the whole cerebellum as a reference region (SUVRWC). The Figure represents the actual cohort
used for this work (amyloid-negative patients, blue points), and patients excluded for being positive according to the
ADNI SUVRWC =1.11 threshold (red and orange dots). The correlation coefficient between WM-SUVRCGM and SUVRWC
when including amyloid-positive patients was r=0.55. Figure 6. Example images for the different levels of processing
for some of the simulated images. Each row shows the original image (left), smoothed image (center-left), atlas used
for the PVC (center). RBV-corrected image (center-right) and iY-corrected image (right), for each of the cases. Figure 7.
Comparison of ground truth and measured SUVRCGM values for RBV (blue lines). Table S1. Measured PF for each of
the scanners present in the ADNI database (measured by the ADNI) and smoothing applied to each of the scanners to
obtain an isotropic 8-mm resolution (as proposed by the ADNI). Table 2. Quantification results for all the analyzed pa-
tients, including the ADNI label for the patient (Patient), the quantified Cortex average (Cortex AVG), cerebellum grey
matter average (CGM AVG), whole cerebellum average (WC AVG), white matter average (WM AVG), SUVRCWM, SUVRWC
and the PET scanner.
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